Welcome, Guest. Please login or register.
July 22, 2024, 06:29:08 pm

Login with username, password and session length

  • Total Posts: 55130
  • Total Topics: 4851
  • Online Today: 204
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 52
Total: 52


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Baraclude and Viread as Treatment for Hepatitis B Yield Comparable Prognoses  (Read 7927 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Whether hepatitis B virus (HBV) is treated with Baraclude (entecavir) or Viread (tenofovir disoproxil fumarate), there is no difference in prognosis when it comes to rates of hepatocellular carcinoma (HCC, the most common form of liver cancer) or the composite outcome of liver transplant or death. So found a recent study by a team of South Korean researchers.

Publishing their findings in the Journal of Hepatology, a research team led by Beom Kyung Kim, MD, of the department of internal medicine at Yonsei University College of Medicine in Seoul, and Yeon Seok Seo, MD, of the department of internal medicine at Korea University College of Medicine, also in Seoul, enrolled in their study 2,897 people with HBV who were first-timers to treatment and who were started on either Baraclude or Viread between 2012 and 2014.

For more...


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.